Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Boston Scientific Corp (BSX)

Boston Scientific Corp (BSX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 90,641,824
  • Shares Outstanding, K 1,486,175
  • Annual Sales, $ 20,074 M
  • Annual Income, $ 2,898 M
  • EBIT $ 4,509 M
  • EBITDA $ 5,923 M
  • 60-Month Beta 0.78
  • Price/Sales 4.76
  • Price/Cash Flow 15.92
  • Price/Book 3.89

Options Overview Details

View History
  • Implied Volatility 48.09% (+3.87%)
  • Historical Volatility 37.23%
  • IV Percentile 99%
  • IV Rank 94.85%
  • IV High 49.76% on 03/27/26
  • IV Low 17.38% on 07/29/25
  • Expected Move (DTE 2) 3.64 (6.11%)
  • Put/Call Vol Ratio 0.42
  • Today's Volume 85,870
  • Volume Avg (30-Day) 26,503
  • Put/Call OI Ratio 0.62
  • Today's Open Interest 270,548
  • Open Int (30-Day) 380,078
  • Expected Range 55.88 to 63.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.80
  • Number of Estimates 9
  • High Estimate $0.86
  • Low Estimate $0.78
  • Prior Year $0.75
  • Growth Rate Est. (year over year) +6.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
59.38 +0.23%
on 04/21/26
71.20 -16.40%
on 03/26/26
-9.96 (-14.34%)
since 03/20/26
3-Month
59.38 +0.23%
on 04/21/26
94.75 -37.18%
on 01/26/26
-32.19 (-35.10%)
since 01/21/26
52-Week
59.38 +0.23%
on 04/21/26
109.50 -45.64%
on 09/09/25
-34.06 (-36.40%)
since 04/21/25

Most Recent Stories

More News
BSX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Boston Scientific To Contact Him Directly To Discuss Their Options

BSX : 59.52 (-2.41%)
BSX Shareholder Alert: May 4, 2026 Lead Plaintiff Deadline in Boston Scientific Corporation Securities Class Action Lawsuit -- The Gross Law Firm

NEW YORK , April 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Boston Scientific Corporation (NYSE: BSX).

BSX : 59.52 (-2.41%)
Boston Scientific (BSX) Q1 Earnings: What To Expect

Boston Scientific (BSX) Q1 Earnings: What To Expect

BSX : 59.52 (-2.41%)
BSX Deadline: BSX Investors Have Opportunity to Lead Boston Scientific Corporation Securities Fraud Lawsuit

NEW YORK , April 20, 2026 /PRNewswire/ -- 

BSX : 59.52 (-2.41%)
Robbins LLP Encourages BSX Stockholders to Contact the Firm for Information About the Class Action Against Boston Scientific

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Boston Scientific Corporation (NYSE: BSX) common stock between July...

BSX : 59.52 (-2.41%)
Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

BENSALEM, Pa. , April 17, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...

BSX : 59.52 (-2.41%)
BSX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Boston Scientific To Contact Him Directly To Discuss Their Options

BSX : 59.52 (-2.41%)
1 Cash-Producing Stock for Long-Term Investors and 2 That Underwhelm

1 Cash-Producing Stock for Long-Term Investors and 2 That Underwhelm

STKL : 6.48 (-0.15%)
BSX : 59.52 (-2.41%)
ACDC : 6.54 (+8.28%)
INVESTOR DEADLINE: Boston Scientific Corporation (BSX) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

SAN DIEGO , April 16, 2026 /PRNewswire/ -- The law firm of  Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Boston Scientific Corporation (NYSE: BSX) common...

BSX : 59.52 (-2.41%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadlines - BSX

NEW YORK , April 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX).  ...

BSX : 59.52 (-2.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and...

See More

Key Turning Points

3rd Resistance Point 63.30
2nd Resistance Point 62.49
1st Resistance Point 61.01
Last Price 59.52
1st Support Level 58.71
2nd Support Level 57.90
3rd Support Level 56.41

See More

52-Week High 109.50
Fibonacci 61.8% 90.36
Fibonacci 50% 84.44
Fibonacci 38.2% 78.53
Last Price 59.52
52-Week Low 59.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.